Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Claudette Falato"'
Autor:
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women w
Externí odkaz:
https://doaj.org/article/7c7d4486147e4021ad5651e0e2b54a88
Autor:
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105043- (2024)
Summary: Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools ai
Externí odkaz:
https://doaj.org/article/e280cec22ed2498189d321ebd159a946
Autor:
Eva M. Gamper, Jammbe Z. Musoro, Corneel Coens, Jean-Jacques Stelmes, Claudette Falato, Mogens Groenvold, Galina Velikova, Kim Cocks, Hans-Henning Flechtner, Madeleine T. King, Andrew Bottomley, on behalf of the EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The aim of the study was to estimate the minimally important difference (MID) for interpreting group-level change over time, both within a group and between groups, for the European Organisation for Research and Treatment of Cance
Externí odkaz:
https://doaj.org/article/45f73d89ca324aa69fe9f618d2e284a3
Autor:
Francisco Javier Muñoz-Carrillo, Laia Paré, Benedetta Conte, Adela Rodríguez, Patricia Galván, Esther Sanfeliu, Blanca González-Farré, Claudette Falato, Isabel Garcia-Fructuoso, Barbara Adamo, Nuria Chic, Olga Martínez-Sáez, Tomás Pascual, Reinaldo Moreno, Montserrat Muñoz, Fara Brasó-Maristany, Aleix Prat, Francesco Schettini, Maria Vidal
Publikováno v:
Cancer Research. 83:P2-23
INTRODUCTION: Breast cancer (BC) is a highly prevalent and heterogeneous disease, entailing different so-called intrinsic subtypes (IS) according to gene expression, namely Luminal A, Luminal B, HER2-Enriched (HER2E) and Basal-like, as well as a norm
Autor:
Guillermo Villacampa, Claudette Falato, Laia Paré, Cristina Hernando, Miriam Arumí, Cristina Saura, Guadalupe Gómez, Montserrat Muñoz, Miguel Gil-Gil, Yann Izarzugaza, Neus Ferrer, Josu Najera-Zuloaga, Alvaro Montaño, Eva Ciruelos, Santiago González-Santiago, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Tomás Pascual
Publikováno v:
European Journal of Cancer. 174:232-242
In the phase II CORALLEEN trial, patients with PAM50 luminal B early breast cancer (EBC) were randomised to neoadjuvant ribociclib plus letrozole (R + L) or chemotherapy based on anthracyclines and taxanes. Results from the primary efficacy analysis
Autor:
Nicholas P. Tobin, Jonas Bergh, Kamila Czene, Charles M. Perou, Theodoros Foukakis, Paul K. Wright, Joseph W. Carlson, Claudette Falato, J. Chuck Harrell, Linda S. Lindström, Arian Lundberg
Supplementary figure S1: Survival analysis (Kaplan-Meier estimates) with Breast cancer specific survival (BCSS) as end point for All patients of Cohort 1. Supplementary figure S2: Flowchart showing simplified results from Cohort 1. Supplementary figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e03cf3ade31369e098b7cdcaa7dffb8
https://doi.org/10.1158/1078-0432.22462326
https://doi.org/10.1158/1078-0432.22462326
Autor:
Nicholas P. Tobin, Jonas Bergh, Kamila Czene, Charles M. Perou, Theodoros Foukakis, Paul K. Wright, Joseph W. Carlson, Claudette Falato, J. Chuck Harrell, Linda S. Lindström, Arian Lundberg
All supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10672b6c46da6f2c9230d140b6ef9003
https://doi.org/10.1158/1078-0432.22462323
https://doi.org/10.1158/1078-0432.22462323
Autor:
Nicholas P. Tobin, Jonas Bergh, Kamila Czene, Charles M. Perou, Theodoros Foukakis, Paul K. Wright, Joseph W. Carlson, Claudette Falato, J. Chuck Harrell, Linda S. Lindström, Arian Lundberg
Supplementary table S1. Cell cycle genes Supplementary table S2. Cross-table of concordance between Ki67 immunohistochemical staining and gene expression signature classifications in Cohorts 1 and 2 Supplementary table S3. Clinico-pathological charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cbc3567dea3f7070548da8c8ab628b1
https://doi.org/10.1158/1078-0432.22462320.v1
https://doi.org/10.1158/1078-0432.22462320.v1
Autor:
Nicholas P. Tobin, Jonas Bergh, Kamila Czene, Charles M. Perou, Theodoros Foukakis, Paul K. Wright, Joseph W. Carlson, Claudette Falato, J. Chuck Harrell, Linda S. Lindström, Arian Lundberg
Purpose: Gene signatures and Ki67 stratify the same breast tumor into opposing good/poor prognosis groups in approximately 20% of patients. Given this discrepancy, we hypothesized that the combination of a clinically relevant signature and IHC marker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654712bb462ece270818c151be44a761
https://doi.org/10.1158/1078-0432.c.6525075
https://doi.org/10.1158/1078-0432.c.6525075
Autor:
Meritxell Bellet, Serafin Morales, Ariadna Gasol, Kepa Amillano, Nuria Chic, Xavier González-Farré, Patricia Villagrasa, Laia Paré, Claudette Falato, Paolo Nuciforo, Débora Martínez, Juan M Ferrero-Cafiero, Tomás Pascual, Aleix Prat, Carol Lange, Cristina Saura
Publikováno v:
Cancer Research. 82:P1-07
Background PgR expression is a biomarker of ER functionality, cellular progression to malignancy, and response to endocrine therapy (ET) in HR+ BC. Onapristone (ONA), a type 1 antiprogestin, was shown to have a single agent anti-tumor activity in pat